Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Trial details
- Registry ID
- NCT06359379
- Drugs studied
- Ropidoxuridine
TrialRedline tracks 1 clinical trial sponsored by Shuttle Pharmaceuticals, Inc.: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT PromoterNCT06359379 | Ropidoxuridine | Terminated | 2025-12-01Actual |
Names as written in the registry records.
NCT06359379 · Shuttle Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 54 participants (planned). After: 30 participants (actual).
Before: Estimated. After: Actual.
Before: Aug 2026. After: 1 Dec 2025.
Before: Recruiting. After: Terminated.